12,372 trials
Pain
Primary: Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel — 276.97; 282.88 NRS Score (0 - 10…
Hypercholesterolemia · Heterozygous Familial Hypercholesterolemia
Primary: Percentage of Participants Who Experience 1 or More Adverse Event (AE) — 82.9; 88.9 Percentage of Participants
Healthy
Primary: Percentage of Subjects Who Have a Seroprotective Immune Response — 90.1; 70.5 Percentage of participants
Arthritis, Rheumatoid
Primary: Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 16 — 26.4; 54.8; 53.5 Percentage of Participants — p=< 0.001
Dyskinesia · Levodopa-Induced Dyskinesia (LID) · Parkinson's Disease (PD)
Primary: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score — -6.3; -20.7 units on a scale — p=<0.0001
Healthy
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Hypogonadism
Primary: Percentage of Patients With Total Testosterone Cavg(0-168h) Serum Concentrations Within the Normal Range (300-1100 ng/dL) — 139 Participants
Ovulatory Dysfunction · Anovulation · Ovulation Induction
Primary: Time to Ovulation With Each Protocol — 31.1; 21.5 days
Moderate Risk of CVD
Primary: Time to the First Occurrence of the Composite Outcome of MI (Myocardial Infarction), Stroke, Cardiovascular Death, UA (Unstable Angina) or TIA (Transient Ischemic…
Breast Cancer
Primary: Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic…
Asthma
Primary: Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) ) — 0.056…
Chronic Thrombocytopenia · Immune Thrombocytopenia
Primary: Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period — 0; 12.4 Weeks — p=<0.0001
Hypercholesterolemia
Primary: Change From Baseline in Percent Atheroma Volume at Week 78 — 0.053; -0.955 percent atheroma volume — p=< 0.0001
Lambert Eaton Myasthenic Syndrome
Primary: Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days — 5.6; 6.4; 7.9; 6.7 QMG Score — p=0.0452
Acute Otitis Media
Primary: The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product — 10; 30 Participants